

- 12 -

Patent claims

1. A pharmaceutical product for preventing or reducing the onset of symptoms of a respiratory disease, or treating or reducing the severity of a respiratory disease, comprising as a free combination
 - (a) an effective amount of roflumilast in a formulation suited for oral or intravenous administration and
 - (b) an effective amount of an anticholinergic agent selected from the group of ipratropium, oxitropium and tiotropium salts in a formulation suited for administration by Inhalation.
2. A pharmaceutical product according to claim 1 for preventing or reducing the onset of symptoms of a respiratory disease, or treating or reducing the severity of a respiratory disease, comprising as a free combination
 - (a) an effective amount of roflumilast in a formulation suited for oral administration and
 - (b) an effective amount of an anticholinergic agent selected from the group of ipratropium, oxitropium and tiotropium salts in a formulation suited for administration by Inhalation.
3. A pharmaceutical product according to claim 1 for preventing or reducing the onset of symptoms of a respiratory disease, or treating or reducing the severity of a respiratory disease, comprising as a free combination
 - (a) an effective amount of roflumilast in a formulation suited for intravenous administration and
 - (b) an effective amount of an anticholinergic agent selected from the group of ipratropium, oxitropium and tiotropium salts in a formulation suited for administration by Inhalation.
4. A pharmaceutical product according to claim 1, 2 or 3 wherein the anticholinergic agent is tiotropium bromide or tiotropium bromide monohydrate.
5. A pharmaceutical product according to claim 1, 2 or 3 wherein the anticholinergic agent is ipratropium bromide.
6. A pharmaceutical product according to claim 1, 2 or 3 wherein the anticholinergic agent is oxitropium bromide.
7. A pharmaceutical product according to any one of claims 1 to 6, wherein roflumilast represents 3-cyclopropylmethoxy-4-difluoromethoxy-N-(3,5-dichloropyrid-4-yl)benzamide.
8. A pharmaceutical product according to any one of claims 1 to 6, wherein roflumilast represents 3-cyclopropylmethoxy-4-difluoromethoxy-N-(3,5-dichloro-1-oxypyrid-4-yl)benzamide.

- 13 -

9. A method for preventing or reducing the onset of symptoms of a respiratory disease, or treating or reducing the severity of a respiratory disease by administering simultaneously or sequentially, close in time or remote in time, in any order whatever to a patient in need thereof (1) an effective amount of roflumilast orally or intravenously and (2) an effective amount of an anticholinergic agent selected from the group of ipratropium, oxitropium and tiotropium salts by inhalation.

10. A method according to claim 9 for preventing or reducing the onset of symptoms of a respiratory disease, or treating or reducing the severity of a respiratory disease by administering simultaneously or sequentially, close in time or remote in time, in any order whatever to a patient in need thereof (1) an effective amount of roflumilast orally and (2) an effective amount of an anticholinergic agent selected from the group of ipratropium, oxitropium and tiotropium salts by inhalation.

11. A method according to claim 9 for preventing or reducing the onset of symptoms of a respiratory disease, or treating or reducing the severity of a respiratory disease by administering simultaneously or sequentially, close in time or remote in time, in any order whatever to a patient in need thereof (1) an effective amount of roflumilast intravenously and (2) an effective amount of an anticholinergic agent selected from the group of ipratropium, oxitropium and tiotropium salts by inhalation.

12. A method according to claim 9, 10 or 11, wherein the two active compounds are administered sequentially, close in time or remote in time, in any order whatever.

13. A method according to claim 9, 10, 11 or 12 wherein the anticholinergic agent is tiotropium bromide or tiotropium bromide monohydrate.

14. A method according to claim 9, 10, 11 or 12 wherein the anticholinergic agent is ipratropium bromide.

15. A method according to claim 9, 10, 11 or 12 wherein the anticholinergic agent is oxitropium bromide.

16. A method according to any one of claims 9 to 15, wherein roflumilast represents 3-cyclopropylmethoxy-4-difluoromethoxy-N-(3,5-dichloropyrid-4-yl)benzamide.

17. A method according to any one of claims 9 to 15, wherein roflumilast represents 3-cyclopropylmethoxy-4-difluoromethoxy-N-(3,5-dichloro-1-oxypyrid-4-yl)benzamide.

18. A method according to any one of claims 9 to 17, wherein the respiratory disease is COPD.

19. Medicament pack, containing (a) roflumilast as active ingredient in a formulation suited for oral or intravenous administration and (b) a description that roflumilast can be administered, for reducing the

- 14 -

onset of symptoms of a respiratory disease, or for treating or reducing the severity of a respiratory disease together with an anticholinergic agent selected from the group of ipratropium, oxitropium and tiotropium salts in a formulation suited for administration by inhalation, sequentially, where the sequential administration is close in time or remote in time and in any order whatever.